Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 4	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 5	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 6	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 7	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 8	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9	MAR 22	EMBASE is now updated on a daily basis
NEWS 10	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 12	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 13	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 15	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 16	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 17	MAY 11	KOREAPAT updates resume
NEWS 18	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 19	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 20	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 21	JUN 02	The first reclassification of IPC codes now complete in INPADOC

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:58:23 ON 25 JUN 2006

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:58:36 ON 25 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUN 2006 HIGHEST RN 889213-08-5
DICTIONARY FILE UPDATES: 23 JUN 2006 HIGHEST RN 889213-08-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information

on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10824731.str



chain nodes :
17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :
2-18 9-17 13-17 18-19 18-20
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16
exact/norm bonds :
2-18 9-17 13-17
exact bonds :
18-19 18-20
normalized bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16
isolated ring systems :
containing 1 : 11 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 11:58:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       12 TO ITERATE

100.0% PROCESSED       12 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           33 TO      447
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 11:58:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      160 TO ITERATE

100.0% PROCESSED      160 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

L3            3 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10824731a.str
```



```
chain nodes :
17
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16
chain bonds :
9-17  13-17
```

ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16
exact/norm bonds :
9-17 13-17
normalized bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16
isolated ring systems :
containing 1 : 11 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 12:00:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 260 TO ITERATE

100.0% PROCESSED 260 ITERATIONS 11 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4233 TO 6167
PROJECTED ANSWERS: 22 TO 418

L5 11 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 12:00:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5002 TO ITERATE

100.0% PROCESSED 5002 ITERATIONS 170 ANSWERS
SEARCH TIME: 00.00.01

```
L6          170 SEA SSS FUL L4

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   334.32     334.53

FILE 'HCAPLUS' ENTERED AT 12:00:18 ON 25 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 25 Jun 2006  VOL 145 ISS 1
FILE LAST UPDATED: 23 Jun 2006  (20060623/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l3
L7            2 L3

=> s l6
L8           35 L6

=> s l8 and py<=2003
      23861848 PY<=2003
L9           28 L8 AND PY<=2003

=> s l9 and p38 kinase
         12541 P38
        266776 KINASE
         52258 KINASES
        275331 KINASE
                 (KINASE OR KINASES)
          2825 P38 KINASE
                 (P38(W)KINASE)
L10          0 L9 AND P38 KINASE

=> s l9 and kinase inhibitors
        266776 KINASE
         52258 KINASES
        275331 KINASE
                 (KINASE OR KINASES)
        518345 INHIBITORS
         20896 KINASE INHIBITORS
```

(KINASE(W)INHIBITORS)
L11 1 L9 AND KINASE INHIBITORS

=> s l9 and us/pc
1557202 US/PC
L12 11 L9 AND US/PC

=> d his

(FILE 'HOME' ENTERED AT 11:58:23 ON 25 JUN 2006)

FILE 'REGISTRY' ENTERED AT 11:58:36 ON 25 JUN 2006
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 3 S L1 SSS FULL
L4 STRUCTURE UPLOADED
L5 11 S L4
L6 170 S L4 SSS FULL

FILE 'HCAPLUS' ENTERED AT 12:00:18 ON 25 JUN 2006
L7 2 S L3
L8 35 S L6
L9 28 S L8 AND PY<=2003
L10 0 S L9 AND P38 KINASE
L11 1 S L9 AND KINASE INHIBITORS
L12 11 S L9 AND US/PC

=> d l7 ibib abs hitstr tot

L7 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:878161 HCAPLUS
DOCUMENT NUMBER: 141:366245
TITLE: Preparation of substituted quinazolines as p38 kinase inhibitors
INVENTOR(S): Dunn, James Patrick; Goldstein, David Michael; Stahl, Christoph Martin; Trejo-Martin, Teresa Alejandra
PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004209904	A1	20041021	US 2004-824731	20040415
AU 2004230209	A1	20041028	AU 2004-230209	20040408
CA 2522522	AA	20041028	CA 2004-2522522	20040408
WO 2004092144	A2	20041028	WO 2004-EP3779	20040408
WO 2004092144	A3	20050324		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1620408	A2	20060201	EP 2004-726448		20040408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
BR 2004009580	A	20060418	BR 2004-9580		20040408
CN 1774425	A	20060517	CN 2004-80010341		20040408
PRIORITY APPLN. INFO.:			US 2003-463467P	P	20030416
			WO 2004-EP3779	W	20040408

OTHER SOURCE(S): MARPAT 141:366245

GI



I



II

AB The title compds. I [R4, R5 = H, halo, CN, haloalkyl, or haloalkoxy (but are not both hydrogen); R6, R7 = alkyl, halo, CN, etc.; Q = a non-aromatic moiety; m = 0-3; n = 0-2] which are useful as p38 kinase inhibitors, were prepared and formulated. E.g., a multi-step synthesis of II, starting from Me 5-chloro-2-nitrobenzoate and 2,4-difluorophenol, which showed IC50 of <0.10 μM against p38 MAP kinase, was given.

IT **778639-20-6P 778639-21-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted quinazolines as p38 kinase inhibitors)

RN 778639-20-6 HCAPLUS

CN 1,2-Propanediol, 3-[[6-(2,4-difluorophenoxy)-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 778639-21-7 HCAPLUS
CN 2-Quinazolinamine, 6-(2,4-difluorophenoxy)-N-[2-(methylsulfonyl)ethyl]-(9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:582372 HCAPLUS
DOCUMENT NUMBER: 142:155900
TITLE: Synthesis and phenotypic screening of a guanine-mimetic library
AUTHOR(S): Miller, Stephen C.; Mitchison, Timothy J.
CORPORATE SOURCE: Department of Cell Biology and Institute of Chemistry and Cell Biology, Harvard Medical School, Boston, MA, 02115, USA
SOURCE: ChemBioChem (2004), 5(7), 1010-1012
CODEN: CBCHFX; ISSN: 1439-4227
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:155900
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Guanine-derived small mols. play important roles in many aspects of cellular function. Proteins that bind guanine and its derivs. control a wide variety of cellular processes, and compds. that disrupt this binding would be valuable research tools as well as potential pharmaceuticals. A split-pool library of 270 6-substituted-2-amino-4(3H)-quinazolinones (I) (R1 = residue of thiol, phenol, or primary alcs.; R2 = aryl or alkyl; e.g. R1 = 3,4-dimethylphenyl, R2 = 3,4,5-trimethoxyphenyl, benzyl; R1 = isobutylthio, R2 = 3-acetylphenyl; R1 = cyclohexylthio, R2 = 4-chlorophenyl) was prepared by aza-Wittig-mediated solid-phase synthesis which involves (1) nucleophilic aromatic substitution of a resin-bound 5-fluoro-2-nitrobenzamide with a variety of thiols, phenols, and primary alcs., (2) generation of a resin-bound iminophosphorane (II) (P = resin) by treatment with Ph3P/Cl3CCCl3/imidazole (3 h, 4°), (3) aza-Wittig reaction of the iminophosphoranes with one of 15 isocyanates (R2-NCO) to yield a carbodiimide (III) (P = resin) followed by intermol. O-attack instead of the desired N attack to the carbodiimide to yield an 4-imino-4H-3,1-benzoxazine (IV), and (4) DBU-mediated isomerization to the desired 2-amino-4(3H)-quinazolinone (V) (P = resin) followed by resin cleavage. The compds. I were cell-permeable guanine-mimetics and screened for (a) the effect on the cytoskeleton and cell cycle progression by incubating the compds. with BS-C-1-(monkey) cells for 6 h, followed by

fixing and staining for actin, DNA, and microtubules and (b) disruption of cellular trafficking. For example, I (R1 = isobutylthio, R2 = 3-acetylphenyl) disrupted both the actin and microtubule cytoskeleton, but did not arrest cells in mitosis.

IT **828261-87-6P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(solid-phase synthesis and phenotypic screening of guanine-mimetic library via aza-Wittig reaction of iminophosphoranes with isocyanates and DBU-mediated isomerization iminobenzoxazines)

RN 828261-87-6 HCAPLUS
CN 4(1H)-Quinazolinone, 6-(3,4-dimethylphenoxy)-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l11 ibib abs hitstr tot

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:568090 HCAPLUS
DOCUMENT NUMBER: 127:248122
TITLE: Quinazoline derivatives as antitumor agents
INVENTOR(S): Barker, Andrew John; Johnstone, Craig
PATENT ASSIGNEE(S): Zeneca Limited, UK
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730034	A1	19970821	WO 1997-GB344	19970210 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2242102	AA	19970821	CA 1997-2242102	19970210 <--
AU 9716126	A1	19970902	AU 1997-16126	19970210 <--
AU 707339	B2	19990708		
EP 880507	A1	19981202	EP 1997-902496	19970210 <--
EP 880507	B1	20050413		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

CN 1211240	A	19990317	CN 1997-192242	19970210 <--
JP 2000504713	T2	20000418	JP 1997-529073	19970210 <--
NZ 330816	A	20000526	NZ 1997-330816	19970210 <--
IL 125685	A1	20021110	IL 1997-125685	19970210 <--
AT 293103	E	20050415	AT 1997-902496	19970210
PT 880507	T	20050729	PT 1997-902496	19970210
ES 2239351	T3	20050916	ES 1997-902496	19970210
ZA 9701231	A	19970814	ZA 1997-1231	19970213 <--
US 5866572	A	19990202	US 1997-796483	19970213 <--
NO 9803707	A	19981013	NO 1998-3707	19980813 <--
NO 311936	B1	20020218		
US 6399602	B1	20020604	US 1998-152070	19980911 <--
US 2003018029	A1	20030123	US 2002-136276	20020502 <--
US 6897214	B2	20050524		

PRIORITY APPLN. INFO.:

GB 1996-3095	A	19960214
WO 1997-GB344	W	19970210
US 1997-796483	A3	19970213
US 1998-152070	A1	19980911

OTHER SOURCE(S): MARPAT 127:248122

GI



I



II

AB The invention concerns quinazoline derivs. I [X1 = bond, CO, C(R2)2, CH(OR2), S, C.tplbond.C, O, S, etc.; Q1 = Ph, naphthyl, or 5- or 6-membered heteroaryl optionally bearing 1-3 substituents; m = 1 or 2; R1 = H, halo, CF3, OH, NH2, cyano, etc.; R2 = H, alkyl; Q2 = Ph or 9- or 10-membered bicyclic heterocycle optionally bearing 1-3 substituents] and their pharmaceutically acceptable salts. Also disclosed are processes for preparation of I and salts, pharmaceutical compns. containing them, and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative diseases such as cancer. Examples include syntheses of 40 compds. and various intermediates. For instance, Pd(PPh3)4-catalyzed coupling of 6-bromo-4-(3-chloro-4-fluoroanilino)quinazoline-HCl with di-iso-Pr [5-(2-morpholinoethyl)thien-2-yl]boronate (prepns. given) gave 27% title compound II. At 50 mg/kg/day in athymic nude mice with human vulval epidermoid carcinoma xenografts (cell line A-431), II gave 64% inhibition of tumor volume (vs. control) after 13 days.

IT **195457-37-5P**, 4-(3-Chloro-4-fluoroanilino)-6-(4-cyanophenoxy)quinazoline **195457-38-6P**, 4-(3-Chloro-4-fluoroanilino)-6-(4-nitrophenoxy)quinazoline **195457-39-7P**, 6-(4-Aminophenoxy)-4-(3-chloro-4-fluoroanilino)quinazoline **195457-41-1P**, 6-[4-(Aminomethyl)phenoxy]-4-(3-chloro-4-

fluoroanilino)quinazoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivs. as antitumor agents and antiproliferatives)

RN 195457-37-5 HCAPLUS
CN Benzonitrile, 4-[[4-[(3-chloro-4-fluorophenyl)amino]-6-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 195457-38-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(4-nitrophenoxy)- (9CI) (CA INDEX NAME)



RN 195457-39-7 HCAPLUS
CN 4-Quinazolinamine, 6-(4-aminophenoxy)-N-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 195457-41-1 HCAPLUS
CN 4-Quinazolinamine, 6-[4-(aminomethyl)phenoxy]-N-(3-chloro-4-fluorophenyl)-(9CI) (CA INDEX NAME)



IT **195457-40-0P**, 4-(3-Chloro-4-fluoroanilino)-6-phenoxyquinazoline
195457-42-2P, 4-(3-Chloro-4-fluoroanilino)-6-[4-(morpholinomethyl)phenoxy]quinazoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as antitumor agents and antiproliferatives)
RN 195457-40-0 HCAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-phenoxy- (9CI) (CA INDEX NAME)



RN 195457-42-2 HCAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-[4-(4-morpholinylmethyl)phenoxy]- (9CI) (CA INDEX NAME)



=> d l12 ibib abs hitstr tot

L12 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:737351 HCAPLUS
DOCUMENT NUMBER: 139:261565
TITLE: Preparation of quinazolinylguanidines, quinolinylguanidines, and N-sulfonyl argininylphenylalaninamides for the treatment of pain
INVENTOR(S): Forray, Carlos C.; Kawakami, Joel; Konkel, Michael J.; Boteju, Lakmal W.; Wetzel, John M.; Noble, Stewart A.; Wan, Honghe
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 47 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003176314	A1	20030918	US 2002-253237		20020924 <--
PRIORITY APPLN. INFO.:			US 2001-324767P	P	20010924

AB Title compds. were prepared for treating pain, urinary incontinence and other abnormalities mediated by a neuropeptide FF (NPFF) receptor. Thus, N-(4-methyl-6-pentyl-2-quinazolinyl)guanidine and 1-naphthalenesulfonyl-Arg-Phe-NH2 were prepared and shown to be agonists concurrently at the NPFF1 and NPFF2 receptors.

IT **503831-93-4P 503831-96-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolinylguanidines, quinolinylguanidines, and N-sulfonyl argininylphenylalaninamides for treatment of pain)

RN 503831-93-4 HCAPLUS
CN Guanidine, (4-methyl-6-phenoxy-2-quinazolinyl)- (9CI) (CA INDEX NAME)



RN 503831-96-7 HCAPLUS
CN Guanidine, [4-methyl-6-(4-methylphenoxy)-2-quinazolinyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:570646 HCAPLUS
DOCUMENT NUMBER: 139:133576
TITLE: Preparation of quinolyl- and quinazolinylguanidines as neuropeptide FF (NPFF) agonists/antagonists for treatment of urge incontinence.
INVENTOR(S): Kawakami, Joel K.; Wetzel, John; Boteju, Lakmal W.; Konkel, Michael J.; Wan, Honghe; Noble, Stewart A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 52 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2003139431 A1 20030724 US 2002-253946 20020921 <--
PRIORITY APPLN. INFO.: US 2001-324559P P 20010924
OTHER SOURCE(S): MARPAT 139:133576
GI



I

AB A method for treating urge incontinence comprises administration of title compds. [I; X = CH, CMe, N; R1-R5 = H, alkyl, alkenyl, alkynyl, cycloalkyl, (substituted) aryl, OH, halogenated ether, NO2, amino, halo, CN, C(Z)R6, C(Z)OR6, C(Z)N(R6)2 , N(R6)C(Z)R6, N(R6)C(Z)N(R6)2, OC(Z)R6, C(Z)OR6, OR6, SR6; Z = O, S; R6 = alkyl, aryl, (CH2)nQ, alkenyl, cycloalkyl, cycloalkenyl, Q = OR7, SR7, N(R7)2, aryl; R7 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl; R2R3 = fused aryl, heteroaryl, cycloalkyl, heterocyclic alkyl ring; R3R4 = fused aryl, heteroaryl, cycloalkyl, heterocyclic alkyl ring; each alkyl, alkenyl, alkynyl, alkoxy group is optionally substituted with Ra; Ra = OH, alkoxy, halo, NO2, amino, CF3, carboxy; each cycloalkyl group is optionally substituted with Rb; Rb = Ra, alkyl, alkenyl, alkynyl, cycloalkyl; each aryl is optionally substituted with R1]. Thus, I (X = CH; R1 = Me; R2, R4, R5 = H; R3 = Cl) at 1 mg/kg i.v. in female rats produced complete inhibition of distention-induced bladder contractions, resulting in a disappearance time of 35 min.

IT **503831-93-4P**, N-(4-Methyl-6-phenoxy-2-quinazolinyl)guanidine
503831-96-7P, N-[4-Methyl-6-(4-methylphenoxy)-2-quinazolinyl]guanidine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinolylguanidines and quinazolinylguanidines as neuropeptide FF (NPFF) agonists/antagonists for treatment of urge incontinence)

RN 503831-93-4 HCAPLUS
CN Guanidine, (4-methyl-6-phenoxy-2-quinazolinyl)- (9CI) (CA INDEX NAME)



RN 503831-96-7 HCAPLUS
CN Guanidine, [4-methyl-6-(4-methylphenoxy)-2-quinazolinyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:335019 HCAPLUS
DOCUMENT NUMBER: 138:346575
TITLE: Imide compounds and their application in optical recording media
INVENTOR(S): Ogiso, Akira; Shiozaki, Hiroyoshi; Ishida, Tsutomu; Tsukahara, Hisashi; Misawa, Tsutami; Inoue, Koji; Koike, Tadashi; Ueno, Keiji; Inatomi, Yuji; Nara, Ryousuke
PATENT ASSIGNEE(S): Mitsui Chemicals, Inc., Japan
SOURCE: PCT Int. Appl., 205 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035407	A1	20030501	WO 2002-JP10939	20021022 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1445115	A1	20040811	EP 2002-777915	20021022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1575236	A	20050202	CN 2002-820890	20021022
JP 2004042596	A2	20040212	JP 2002-324789	20021108
US 2005208425	A1	20050922	US 2004-493034	20040419 <--

PRIORITY APPLN. INFO.:

JP 2001-323900	A	20011022
JP 2001-344742	A	20011109
JP 2002-147538	A	20020522
JP 2002-210949	A	20020719
JP 2002-244776	A	20020826
JP 2002-246872	A	20020827
WO 2002-JP10939	W	20021022

OTHER SOURCE(S): MARPAT 138:346575
AB An optical recording medium contains in its recording layer at least one imide compound having a metallocene substitution group.

IT **516516-47-5 516517-77-4 516518-99-3**
RL: MOA (Modifier or additive use); USES (Uses)
(metallocene-containing imide compds. optical recording media)

RN 516516-47-5 HCAPLUS
CN Ferrocene, [2-[7-[1,4-dihydro-4-oxo-6-(3-phenoxyphenoxy)-2-quinazolinyl]-3,6,7,8-tetrahydro-1,3,6,8-tetraoxoindeno[5,6-f]isoindol-2(1H)-yl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 516517-77-4 HCAPLUS
CN Ferrocene, 1,1'',1''''-[2-[6-[1,4-dihydro-4-oxo-6-(3-phenoxyphenoxy)-2-quinazolinyl]-3,5,6,7-tetrahydro-1,3,5,7-tetraoxocyclopent[f]isoindol-2(1H)-yl]-1,3,5-benzenetriyl]tris- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 516518-99-3 HCAPLUS
CN Ferrocene, 1,1'',1''''-[2-[7-[1,4-dihydro-4-oxo-6-(3-phenoxyphenoxy)-2-quinazolinyl]-3,6,7,8-tetrahydro-1,3,6,8-tetraoxonaphth[2,1,8-def]isoquinolin-2(1H)-yl]-1,3,5-benzenetriyl]tris- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:301049 HCAPLUS
DOCUMENT NUMBER: 138:321058
TITLE: C2-, C6- and 9-Aryl-substituted purine and other

heteroaryl kinase inhibitor scaffolds and methods for their preparation

INVENTOR(S): Ding, Sheng; Ding, Qiang; Gray, Nathanael S.
PATENT ASSIGNEE(S): IRM LLC, Bermuda
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003031406	A2	20030417	WO 2002-US32680	20021012 <--
WO 2003031406	A3	20060105		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2463563	AA	20030417	CA 2002-2463563	20021012 <--
US 2003191312	A1	20031009	US 2002-270030	20021012 <--
JP 2005512972	T2	20050512	JP 2003-534390	20021012
EP 1578722	A2	20050928	EP 2002-776216	20021012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2006009642	A1	20060112	US 2005-223429	20050909 <--

PRIORITY APPLN. INFO.:

US 2001-328763P	P	20011012
US 2001-331835P	P	20011120
US 2002-346480P	P	20020107
US 2002-348089P	P	20020110
US 2001-328741P	P	20011012
US 2002-346552P	P	20020107
US 2002-347037P	P	20020108
US 2002-170031	A3	20020612
WO 2002-US32680	W	20021012

OTHER SOURCE(S): CASREACT 138:321058; MARPAT 138:321058
GI



I

AB General methods for the solution phase as well as solid phase synthesis of various substituted heteroaryls, particularly C2-, C6- and 9-aryl-substituted purines (e.g. 2-(2,4-dimethoxyphenyl)-6-(4-methoxybenzylamino)-9-isopropylpurine), was demonstrated. These substituted heteroaryls can be further elaborated by aromatic substitution

with amines at elevated temperature or by anilines, boronic acids and phenols via Pd catalyzed cross-coupling reactions. The 1st claim comprises a method of preparing a C2-substituted purine compound, said method comprising: reacting a C2-halogenated purine with A-X (X = -B(OH)2, -OH, and -NHR1; R1 = H, (un)substituted alkyl; A = (un)substituted alkyl, (un)substituted aryl, (un)substituted heterocyclyl) in the presence of a solvent, a base, a carbene ligand and a Pd catalyst. The 2nd claims narrows the 1st claim to purines I wherein R2 = H, (un)substituted alkyl, (un)substituted aryl, (un)substituted heterocyclyl; X' = direct bond, NR1 and O; X'' = direct bond, O and NR3, with the proviso that when X'' is NR3, Y is R4 or A', and when X' is O or a direct bond, Y is A'; A' = (un)substituted alkyl, (un)substituted aryl, (un)substituted arylalkyl, (un)substituted heterocyclyl; R3 = H, (un)substituted alkyl; and R4 = (un)substituted alkyl. Similar claims pertain to C6-substituted purines. Also claimed is a method of preparing a 9-aryl substituted purines, the method comprising: reacting a 2,6-dihalogenated purine with Ar-B(OH)2 (Ar = (un)substituted aryl, and (un)substituted heterocyclyl) in the presence of a solvent and a Cu catalyst. Also claimed is a method for synthesizing a substituted heteroaryl, the method comprising: providing a dihaloheteroaryl scaffold moiety and capturing the dihaloheteroaryl scaffold moiety on a resin by nucleophilic substitution of a 1st halogen by a resin-bound amine nucleophile to afford a resin-bound amine substituted monohaloheteroaryl. Substitution of the 2nd halogen is done by nucleophilic displacement (e.g. by aniline, phenol, amine, boronic acid) or coupling (e.g. palladium-mediated). An initial substitution (e.g. alkylation, acylation, coupling) can be done prior to substitution of the 1st halogen. Example procedures are included for: boronic acid coupling, aniline coupling, phenol coupling, purine N9 arylation via boronic acids/cupric acetate, reductive amination for synthesis of PAL-resin-bound amine, resin capture of dichloroheterocycles, substitution of remaining chloro group with boronic acids via Suzuki coupling and product cleavage, substitution of remaining chloro group with anilines or amines via palladium-catalyzed reaction and product cleavage, substitution of remaining chloro group with phenols via palladium-catalyzed reaction and product cleavage, substitution of remaining chloro group with amines via non-palladium-catalyzed amination reaction without base and product cleavage, and substitution of remaining chloro group with amines via non-palladium-catalyzed amination reaction with KOtBu as base and product cleavage. Tables of purity and yields for various heteroaryl combinatorial libraries are included as validation of the following methods: palladium catalyzed cross-coupling reactions for derivatizing resin-bound 2-chloro-6-aminopurine with boronic acids, anilines, amines and phenols, resin-bound chloroheterocyclic scaffolds which can be derivatized via Suzuki coupling reaction, resin-bound chloroheterocyclic scaffolds which can be derivatized via palladium catalyzed amination reaction, and resin-bound chloroheterocyclic scaffolds which can be derivatized via palladium catalyzed C-O bond formation reaction.

IT **406932-80-7P**, 4-(4-Methoxybenzylamino)-6-(4-methoxyphenoxy)quinazoline
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(C2-, C6- and 9-Aryl-substituted purine and other heteroaryl kinase inhibitor scaffolds and methods for their preparation)

RN 406932-80-7 HCAPLUS

CN 4-Quinazolinamine, 6-(4-methoxyphenoxy)-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L12 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:171851 HCAPLUS
DOCUMENT NUMBER: 136:232110
TITLE: Preparation of phenoxybenzylamines as selective serotonin re-uptake inhibitors
INVENTOR(S): Adam, Mavis Diane; Andrews, Mark David; Elliott, Mark Leonard; Gymer, Geoffrey Edward; Hepworth, David; Howard, Harry Ralph, Jr.; Middleton, Donald Stuart; Stobie, Alan
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018333	A1	20020307	WO 2001-IB1521	20010822 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2420969	AA	20020307	CA 2001-2420969	20010822 <--
AU 2001078650	A5	20020313	AU 2001-78650	20010822 <--
EP 1313701	A1	20030528	EP 2001-956734	20010822 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013610	A	20030624	BR 2001-13610	20010822 <--
JP 2004507523	T2	20040311	JP 2002-523451	20010822
NZ 523951	A	20040924	NZ 2001-523951	20010822
EE 200300084	A	20050215	EE 2003-84	20010822
US 2003060456	A1	20030327	US 2001-941177	20010827 <--
US 6610747	B2	20030826		
BG 107544	A	20031031	BG 2003-107544	20030207 <--

ZA 2003001383	A	20040402	ZA 2003-1383		20030220
NO 2003000842	A	20030428	NO 2003-842		20030224 <--
HR 2003000141	A1	20030430	HR 2003-141		20030226 <--
PRIORITY APPLN. INFO.:			GB 2000-21593	A	20000831
			GB 2001-7116	A	20010321
			US 2000-240271P	P	20001013
			US 2001-292400P	P	20010521
			WO 2001-IB1521	W	20010822

OTHER SOURCE(S): MARPAT 136:232110
GI



I



II

AB Title compds. I [R1 and R2 independently = H, alkyl or (CH2)n(C3-C6cycloalkyl) wherein n = 0, 1, 2 or 3; or R1 and R2 together with the nitrogen to which they are attached from an azetidine ring; Z or Y is -SR3 and the other Z or Y is halogen or -R3; wherein R3 = C1-4 alkyl optionally substituted with fluorine; except that R3 is not CF3; or Z and Y are linked so that, together with the interconnecting atoms, Z and Y form a fused 5 to 7-membered carbocyclic or heterocyclic ring, and wherein when Z and Y form a heterocyclic ring, in addition to carbon atoms, the linkage contains one or two heteroatoms independently selected from O, S and N; R4 and R5 independently = A-X, wherein A = -CH=CH- or -(CH2)p- where p is 0, 1 or 2; X = H, halo, CONR6R7, SO2NR6R7, SO2NHC(=O)R6, OH, C1-4alkoxy, etc; or A-X = (un)substituted 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O; R6 and R7 independently = H, (un)substituted alkyl; or R6 and R7 together with the N to which they are attached form a (un)substituted 4-6 membered heterocyclic ring] and there pharmaceutically acceptable salts are prepared Thus, II was prepared via substitution of 5-(aminosulfonyl)-2-fluoro-N-methylbenzamide by 2,3-dihydrobenzo[b]thiophen-5-ol with successive BF3·THF catalyzed amide reduction, formylation of secondary amine, and reduction II demonstrated a serotonin re-uptake inhibition IC50 of 4.7nM. I inhibit monoamine re-uptake and in particular exhibit activity as selective serotonin reuptake inhibitors.

IT **402911-71-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of serotonin re-uptake inhibitors phenoxybenzylamines)

RN 402911-71-1 HCAPLUS

CN Benzaldehyde, 2-(6-quinazolinyloxy)- (9CI) (CA INDEX NAME)



IT **402910-46-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of serotonin re-uptake inhibitors phenoxybenzylamines)
RN 402910-46-7 HCAPLUS
CN Benzenemethanamine, N,N-dimethyl-2-(6-quinazolinyloxy)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:282401 HCAPLUS
DOCUMENT NUMBER: 128:321653
TITLE: Preparation of alkynyl- and azido-substituted 4-anilinoquinazolines for the treatment of hyperproliferative diseases
INVENTOR(S): Schnur, Rodney Caughren; Arnold, Lee Daniel
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 23 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5747498	A	19980505	US 1996-653786	19960528 <--
PRIORITY APPLN. INFO.:			US 1996-653786	19960528

OTHER SOURCE(S): CASREACT 128:321653; MARPAT 128:321653
GI



I

AB The title compds. [I; R1 = H, halo, OH, etc.; R2 = H, (un)substituted C1-6 alkyl; R3 = H, halo, OH, etc.; R4 = N3, (un)substituted ethynyl; m = 1-3; n = 1-2] and their salts, useful in the treatment of hyperproliferative diseases such as cancer, were prepared Thus, reaction of 4-chloro-6,7-dimethoxyquinazoline with 4-azidoaniline hydrochloride in iPrOH afforded 98% I [R1 = 6,7-Me2; R2, R3 = H; R4 = 4-N3]. Compds. I showed IC50 of 0.0001-30 μM against EGFR kinase.

IT **207225-62-5P 207225-66-9P 207225-68-1P**
207225-69-2P 207225-70-5P 207225-77-2P
207225-78-3P 207225-79-4P 207225-80-7P
207225-81-8P 207225-82-9P 207225-83-0P
207225-85-2P 207225-86-3P 207225-87-4P
207225-89-6P 207225-90-9P 207225-92-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alkynyl- and azido-substituted 4-anilinoquinazolines for the treatment of hyperproliferative diseases)

RN 207225-62-5 HCAPLUS

CN 4-Quinazolinamine, 7-chloro-6-[4-[(4-chlorophenyl)thio]phenoxy]-N-(3-ethynylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-66-9 HCAPLUS

CN 4-Quinazolinamine, 7-chloro-6-(4-chlorophenoxy)-N-(3-ethynylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-68-1 HCAPLUS
CN 4-Quinazolinamine, 7-chloro-N-(3-ethynylphenyl)-6-(4-methoxyphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-69-2 HCAPLUS
CN 4-Quinazolinamine, 7-chloro-N-(3-ethynylphenyl)-6-(4-fluorophenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-70-5 HCAPLUS
CN 4-Quinazolinamine, 6-(4-chlorophenoxy)-N-(3-ethynylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-77-2 HCAPLUS
CN 4-Quinazolinamine, 7-chloro-6-(3-chlorophenoxy)-N-(3-ethynylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-78-3 HCAPLUS
CN 4-Quinazolinamine, 6-(3-bromophenoxy)-7-chloro-N-(3-ethynylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-79-4 HCAPLUS
CN 4-Quinazolinamine, 7-chloro-N-(3-ethynylphenyl)-6-phenoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-80-7 HCAPLUS
CN 4-Quinazolinamine, 7-chloro-N-(3-ethynylphenyl)-6-[4-(methylthio)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-81-8 HCAPLUS
CN 4-Quinazolinamine, 7-chloro-N-(3-ethynylphenyl)-6-[4-(methylsulfonyl)phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-82-9 HCAPLUS
CN 4-Quinazolinamine, 7-chloro-N-(3-ethynylphenyl)-6-(4-methylphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-83-0 HCAPLUS
CN 4-Quinazolinamine, N-(3-ethynylphenyl)-6-(4-phenoxyphenoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-85-2 HCAPLUS
CN 4-Quinazolinamine, 6-(3-chlorophenoxy)-N-(3-ethynylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-86-3 HCAPLUS
CN 4-Quinazolinamine, 6-(3,5-dichlorophenoxy)-N-(3-ethynylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-87-4 HCAPLUS
CN 4-Quinazolinamine, 6-(2-chlorophenoxy)-N-(3-ethynylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-89-6 HCAPLUS
CN 4-Quinazolinamine, 6-(3,4-dichlorophenoxy)-N-(3-ethynylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-90-9 HCAPLUS
CN 4-Quinazolinamine, 6-(4-bromophenoxy)-N-(3-ethynylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 207225-92-1 HCAPLUS
CN 4-Quinazolinamine, 6-(4-chloro-2-methylphenoxy)-N-(3-ethynylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:568090 HCAPLUS
DOCUMENT NUMBER: 127:248122
TITLE: Quinazoline derivatives as antitumor agents
INVENTOR(S): Barker, Andrew John; Johnstone, Craig
PATENT ASSIGNEE(S): Zeneca Limited, UK
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730034	A1	19970821	WO 1997-GB344	19970210 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2242102	AA	19970821	CA 1997-2242102	19970210 <--
AU 9716126	A1	19970902	AU 1997-16126	19970210 <--
AU 707339	B2	19990708		
EP 880507	A1	19981202	EP 1997-902496	19970210 <--
EP 880507	B1	20050413		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1211240	A	19990317	CN 1997-192242	19970210 <--
JP 2000504713	T2	20000418	JP 1997-529073	19970210 <--
NZ 330816	A	20000526	NZ 1997-330816	19970210 <--
IL 125685	A1	20021110	IL 1997-125685	19970210 <--
AT 293103	E	20050415	AT 1997-902496	19970210
PT 880507	T	20050729	PT 1997-902496	19970210
ES 2239351	T3	20050916	ES 1997-902496	19970210
ZA 9701231	A	19970814	ZA 1997-1231	19970213 <--

US 5866572	A	19990202	US 1997-796483	19970213 <--
NO 9803707	A	19981013	NO 1998-3707	19980813 <--
NO 311936	B1	20020218		
US 6399602	B1	20020604	US 1998-152070	19980911 <--
US 2003018029	A1	20030123	US 2002-136276	20020502 <--
US 6897214	B2	20050524		

PRIORITY APPLN. INFO.:

GB 1996-3095	A	19960214
WO 1997-GB344	W	19970210
US 1997-796483	A3	19970213
US 1998-152070	A1	19980911

OTHER SOURCE(S): MARPAT 127:248122

GI



AB The invention concerns quinazoline derivs. I [X1 = bond, CO, C(R2)2, CH(OR2), S, C.tplbond.C, O, S, etc.; Q1 = Ph, naphthyl, or 5- or 6-membered heteroaryl optionally bearing 1-3 substituents; m = 1 or 2; R1 = H, halo, CF3, OH, NH2, cyano, etc.; R2 = H, alkyl; Q2 = Ph or 9- or 10-membered bicyclic heterocycle optionally bearing 1-3 substituents] and their pharmaceutically acceptable salts. Also disclosed are processes for preparation of I and salts, pharmaceutical compns. containing them, and the use of their receptor tyrosine kinase inhibitory properties in the treatment of proliferative diseases such as cancer. Examples include syntheses of 40 compds. and various intermediates. For instance, Pd(PPh3)4-catalyzed coupling of 6-bromo-4-(3-chloro-4-fluoroanilino)quinazoline-HCl with di-iso-Pr [5-(2-morpholinoethyl)thien-2-yl]boronate (prepns. given) gave 27% title compound II. At 50 mg/kg/day in athymic nude mice with human vulval epidermoid carcinoma xenografts (cell line A-431), II gave 64% inhibition of tumor volume (vs. control) after 13 days.

IT **195457-37-5P**, 4-(3-Chloro-4-fluoroanilino)-6-(4-cyanophenoxy)quinazoline **195457-38-6P**, 4-(3-Chloro-4-fluoroanilino)-6-(4-nitrophenoxy)quinazoline **195457-39-7P**, 6-(4-Aminophenoxy)-4-(3-chloro-4-fluoroanilino)quinazoline **195457-41-1P**, 6-[4-(Aminomethyl)phenoxy]-4-(3-chloro-4-fluoroanilino)quinazoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivs. as antitumor agents and antiproliferatives)

RN 195457-37-5 HCAPLUS

CN Benzonitrile, 4-[[4-[(3-chloro-4-fluorophenyl)amino]-6-quinazolinyl]oxy]- (9CI) (CA INDEX NAME)



RN 195457-38-6 HCAPLUS
CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-(4-nitrophenoxy)- (9CI) (CA INDEX NAME)



RN 195457-39-7 HCAPLUS
CN 4-Quinazolinamine, 6-(4-aminophenoxy)-N-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 195457-41-1 HCAPLUS
CN 4-Quinazolinamine, 6-[4-(aminomethyl)phenoxy]-N-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)



IT **195457-40-0P**, 4-(3-Chloro-4-fluoroanilino)-6-phenoxyquinazoline
195457-42-2P, 4-(3-Chloro-4-fluoroanilino)-6-[4-(morpholinomethyl)phenoxy]quinazoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as antitumor agents and antiproliferatives)

RN 195457-40-0 HCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-phenoxy- (9CI) (CA INDEX NAME)



RN 195457-42-2 HCAPLUS

CN 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-6-[4-(4-morpholinylmethyl)phenoxy]- (9CI) (CA INDEX NAME)



L12 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:467270 HCAPLUS
DOCUMENT NUMBER: 125:168006
TITLE: Preparation of 2,4-diaminoquinazolines as insecticides
INVENTOR(S): Henrie, Robert N., II; Peake, Clinton J.; Cullen, Thomas G.; Lew, Albert C.; Chaguturu, Munirathnam K.; Ray, Partha S.; Yeager, Walter H.; Silverman, Ian R.; Buser, John W.; et al.
PATENT ASSIGNEE(S): FMC Corp., USA
SOURCE: U.S., 63 pp., Cont.-in-part of U.S. Ser. No. 149,491, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5534518	A	19960709	US 1994-267340	19940628 <--
ZA 9401038	A	19940825	ZA 1994-1038	19940215 <--
US 5616718	A	19970401	US 1995-426541	19950420 <--
US 5874579	A	19990223	US 1996-640610	19960501 <--
PRIORITY APPLN. INFO.:			US 1993-19389 B2	19930218
			US 1993-149491 B2	19931109
			US 1994-267340 A3	19940628

OTHER SOURCE(S): MARPAT 125:168006
GI



I



II

AB Title compds. [I; R1,R6 = H or alkyl; R2,R7 = H, alkyl, alkanoyl, alkoxycarbonyl, etc.; R1R2 = O-interrupted alkylene; R1R2,R6R7 = dialkylaminomethylene, pyrrolidinomethylene, etc.; R3,R5,R6 = H halo, alkyl, alkoxy, etc.; R4 = H halo, alkyl, alkoxy, substituted aryl(oxy), NHCH2C6H4(CO2H)-4, etc.] were prepared Thus, 2-methyl-6-nitrobenzonitrile was converted in 4 steps to 2-amino-5-ethynyl-6-methylbenzonitrile which was arylated with 4-IC6H4CF3 and the product condensed with ClC(:NH)NH2.HCl to give title compound II which gave 90 and 100% kill of Trichoplusia ni and Spodoptera exigua, resp., at 30ppm foliar spray.

IT **38713-64-3P 38713-65-4P 38713-66-5P**
180269-50-5P 180269-51-6P 180269-52-7P
180269-53-8P 180269-54-9P 180269-55-0P
180269-83-4P 180269-84-5P 180269-85-6P
180269-86-7P 180269-87-8P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,4-diaminoquinazolines as insecticides)

RN 38713-64-3 HCAPLUS
CN 2,4-Quinazolinediamine, 6-(3,5-dichlorophenoxy)- (9CI) (CA INDEX NAME)



RN 38713-65-4 HCAPLUS
CN 2,4-Quinazolinediamine, 6-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 38713-66-5 HCAPLUS
CN 2,4-Quinazolinediamine, 6-[3,5-bis(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 180269-50-5 HCAPLUS

CN 2,4-Quinazolinediamine, 6-(3-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 180269-51-6 HCAPLUS
CN 2,4-Quinazolinediamine, 6-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 180269-52-7 HCAPLUS
CN 2,4-Quinazolinediamine, 6-(2-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 180269-53-8 HCAPLUS
CN 2,4-Quinazolinediamine, 6-[2-chloro-6-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 180269-54-9 HCAPLUS
CN 2,4-Quinazolinediamine, 6-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 180269-55-0 HCAPLUS
CN 2,4-Quinazolinediamine, 6-(2,6-dichlorophenoxy)- (9CI) (CA INDEX NAME)



RN 180269-83-4 HCAPLUS
CN 2,4-Quinazolinediamine, 6-(2-chlorophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 180269-84-5 HCAPLUS
CN 2,4-Quinazolinediamine, 6-(3-chlorophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 180269-85-6 HCAPLUS
CN 2,4-Quinazolinediamine, 6-(4-chlorophenoxy)-5-methyl- (9CI) (CA INDEX NAME)



RN 180269-86-7 HCAPLUS
CN 2,4-Quinazolinediamine, 5-methyl-6-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 180269-87-8 HCAPLUS
CN 2,4-Quinazolinediamine, 5-methyl-6-[2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



L12 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1989:95260 HCAPLUS
DOCUMENT NUMBER: 110:95260
TITLE: Preparation of trans-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]quinazolin-4(3H)-ones as anticoccidial agents
INVENTOR(S): Glazer, Edward A.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 17 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4762838	A	19880809	US 1987-67766	19870622 <--
WO 9312795	A1	19930708	WO 1985-US1685	19850830 <--
W: US				
US 4849518	A	19890718	US 1988-173207	19880324 <--
US 4920224	A	19900424	US 1989-322736	19890313 <--

PRIORITY APPLN. INFO.: WO 1985-US1685 W 19850830
US 1987-67766 A3 19870622
US 1988-173207 A3 19880324
OTHER SOURCE(S): CASREACT 110:95260; MARPAT 110:95260
GI



I



II

AB The title compds. (I, II; R = C1-4 alkylthio; R1 = CF3, C1-4 alkylthio, cyano, 4-picolylthio, 3,5-Cl2C6H3O, Y1C6H4O, Y2C6H4CH2S; R2 = R = H; X = Br, Cl, F, iodo, in 6- or 7-position; X1 = H, MeO, X, in 7- or 8-position; Y1 = H, Br, Cl, F, PhO, Y2 = Br, Cl; when X1 = H then Y1 = H) and their pharmaceutically acceptable salts were prepared as coccidiostats. 4,5,2-Cl2(O2N)C6H2CO2H was phenoxylated with 4-ClC6H4OH and the product hydrogenated to give 2-amino-4-chloro-5-(4-chlorophenoxy)benzoic acid. The latter was cyclized by heating at 155° in H2CO to give 7-chloro-6-(4-chlorophenoxy-4(3H)-quinazolinone which was N-alkylated with allyl trans-2-(3-bromo-2-oxopropyl)-3-methoxy-1-piperidinecarboxylate to give II (R1 = 4-ClC6H4O, R2 = Me, R3 = CO2CH2CH:CH2, X1 = 7-Cl). This was stirred at room temperature in 33% HBr/HOAc to give II.2HBr (R3 = H, other groups unchanged) which was refluxed in 48% HBr to give II.2HBr (R1 = 4-ClC6H4O, R2 = R3 = H, X1 = 7-Cl). Selected I gave 90-100% control of Eimera tenella in chicks at 25 ppm in feed.

IT **117297-62-8P 117297-63-9P 117297-64-0P**
117297-65-1P 117297-66-2P 117297-67-3P
117297-68-4P 117323-95-2P 117323-96-3P
117323-97-4P 117323-98-5P 117348-69-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of coccidiostats)

RN 117297-62-8 HCAPLUS
CN 4(1H)-Quinazolinone, 6-phenoxy- (9CI) (CA INDEX NAME)



RN 117297-63-9 HCAPLUS
CN 4(1H)-Quinazolinone, 6-(4-bromophenoxy)- (9CI) (CA INDEX NAME)



RN 117297-64-0 HCAPLUS
CN 4(1H)-Quinazolinone, 6-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 117297-65-1 HCAPLUS
CN 4(1H)-Quinazolinone, 6-(3-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 117297-66-2 HCAPLUS
CN 4(1H)-Quinazolinone, 6-(3,5-dichlorophenoxy)- (9CI) (CA INDEX NAME)



RN 117297-67-3 HCAPLUS
CN 4(1H)-Quinazolinone, 6-(4-phenoxyphenoxy)- (9CI) (CA INDEX NAME)



RN 117297-68-4 HCAPLUS
CN 4(1H)-Quinazolinone, 6-(4-bromophenoxy)-7-chloro- (9CI) (CA INDEX NAME)



RN 117323-95-2 HCAPLUS
CN 4(1H)-Quinazolinone, 7-chloro-6-(4-fluorophenoxy)- (9CI) (CA INDEX NAME)



RN 117323-96-3 HCAPLUS
CN 4(1H)-Quinazolinone, 7-bromo-6-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 117323-97-4 HCAPLUS
CN 4(1H)-Quinazolinone, 7-chloro-6-(3-chlorophenoxy)- (9CI) (CA INDEX NAME)



RN 117323-98-5 HCAPLUS
CN 4(1H)-Quinazolinone, 6-(3-bromophenoxy)-7-chloro- (9CI) (CA INDEX NAME)



RN 117348-69-3 HCAPLUS
CN 4(1H)-Quinazolinone, 7-chloro-6-(4-chlorophenoxy)- (9CI) (CA INDEX NAME)



IT **117324-60-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as coccidostat intermediate)
RN 117324-60-4 HCAPLUS
CN 4(1H)-Quinazolinone, 6-(2-chlorophenoxy)- (9CI) (CA INDEX NAME)



L12 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1983:405644 HCAPLUS
DOCUMENT NUMBER: 99:5644
TITLE: Herbicidal derivatives of 5-phenoxy-4(3H)-quinazolinone 1-oxide
INVENTOR(S): Steffens, James J.
PATENT ASSIGNEE(S): Rhone-Poulenc Agrochimie, Fr.
SOURCE: U.S., 3 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4377408	A	19830322	US 1981-286747	19810727 <--
PRIORITY APPLN. INFO.:			US 1981-286747	19810727

OTHER SOURCE(S): CASREACT 99:5644; MARPAT 99:5644

GI



I



II

AB The herbicidal (no data) title compds. I [R = trihalomethyl; R1 = halo, R2 = H, (un)substituted C1-5 alkyl] were prepared Thus, 2,5-Cl(F3C)C6H3OC6H3(CONH2)NO2-3,4 was reduced and the resulting amine cyclized with HC(OEt)3 to give the quinazolinone II, which was oxidized with H2O, to give I (R = F3C, R1 = Cl, R2 = H).

IT **86009-58-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidation of)

RN 86009-58-7 HCAPLUS

CN 4(1H)-Quinazolinone, 6-[2-chloro-4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



IT **86009-59-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 86009-59-8 HCAPLUS

CN 4(3H)-Quinazolinone, 6-[2-chloro-4-(trifluoromethyl)phenoxy]-, 1-oxide (9CI) (CA INDEX NAME)



L12 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1981:587290 HCAPLUS

DOCUMENT NUMBER: 95:187290

TITLE: Quinazoline derivatives and pharmaceutical

compositions containing them
INVENTOR(S): Ueda, Ikuo; Kato, Masayuki; Nagano, Masanobu
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd. , Japan
SOURCE: Eur. Pat. Appl., 120 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 30156	A1	19810610	EP 1980-304335	19801202 <--
EP 30156	B1	19840321		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4377580	A	19830322	US 1980-210340	19801125 <--
AU 8064733	A1	19810611	AU 1980-64733	19801126 <--
AU 541811	B2	19850124		
DK 8005139	A	19810604	DK 1980-5139	19801202 <--
CA 1157858	A1	19831129	CA 1980-365968	19801202 <--
AT 6778	E	19840415	AT 1980-304335	19801202 <--
JP 56095174	A2	19810801	JP 1980-170459	19801203 <--
JP 05002679	B4	19930113		
ES 497426	A1	19820601	ES 1980-497426	19801203 <--
ES 507995	A1	19821001	ES 1981-507995	19811215 <--
ES 507996	A1	19821001	ES 1981-507996	19811215 <--
ES 507994	A1	19821116	ES 1981-507994	19811215 <--
US 4429126	A	19840131	US 1982-384998	19820604 <--
US 4543356	A	19850924	US 1983-455411	19830103 <--
CA 1169062	A2	19840612	CA 1983-432297	19830712 <--
JP 05294946	A2	19931109	JP 1991-201541	19910509 <--
JP 06051686	B4	19940706		

PRIORITY APPLN. INFO.:

GB 1979-41607	A	19791203
GB 1980-31965	A	19801003
US 1980-210340	A2	19801125
CA 1980-365968	A3	19801202
EP 1980-304335	A	19801202

OTHER SOURCE(S): CASREACT 95:187290; MARPAT 95:187290
GI



I



II

AB The title compds. I, II [R, R1 = esterified carboxy; R2, R3 = H, alkyl, halo, NO2, NH2, alkoxy, aryloxy, etc.; R4 = H, carboxy, esterified carboxy; X = N:CR5 (R5 = H, alkyl, OH, alkoxy, alkenyloxy, dialkylamino, etc.), R6NCO (R6 = alkyl, alkenyl), etc.] were prepared Thus, stirring

4-aminoquinazoline with EtOCH:C(CO2Et)2 in DMF 1 h at 160° gave di-Et [(4-quinazolinylamino)methylene]propanedioate. I and II are antiallergic agents (test data given).

IT **79689-26-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with alkoxymethylenepropanedioate)

RN 79689-26-2 HCAPLUS
CN 4-Quinazolinamine, 6-phenoxy- (9CI) (CA INDEX NAME)



IT **79689-59-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 79689-59-1 HCAPLUS
CN Propanedioic acid, [[(6-phenoxy-4-quinazolinyl)amino]methylene]-, diethyl ester (9CI) (CA INDEX NAME)



=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	117.08	451.61

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.50	-10.50

FILE 'REGISTRY' ENTERED AT 12:10:53 ON 25 JUN 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 JUN 2006 HIGHEST RN 889213-08-5
DICTIONARY FILE UPDATES: 23 JUN 2006 HIGHEST RN 889213-08-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10824731b.str



chain nodes :
17 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :
2-19 9-17 13-17 19-20
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
2-19 9-17 13-17
exact bonds :
19-20
normalized bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 1 : 11 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 19:CLASS 20:CLASS

L13 STRUCTURE UPLOADED

=> d l13
L13 HAS NO ANSWERS
L13 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l13
SAMPLE SEARCH INITIATED 12:11:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 33 TO 447
PROJECTED ANSWERS: 1 TO 80

L14 1 SEA SSS SAM L13

=> s l13 sss full
FULL SEARCH INITIATED 12:11:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 160 TO ITERATE

100.0% PROCESSED 160 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

L15 3 SEA SSS FUL L13

=>
Uploading C:\Program Files\Stnexp\Queries\10824731c.str



chain nodes :
17 19 20 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :
2-19 9-17 13-17 19-20 20-22
ring bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16
exact/norm bonds :
2-19 9-17 13-17 19-20 20-22
normalized bonds :
1-2 1-6 2-3 3-4 4-7 5-6 5-10 6-7 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16
isolated ring systems :
containing 1 : 11 :

G1:Cb,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 19:CLASS 20:CLASS
22:CLASS

L16 STRUCTURE UPLOADED

=> d l16
L16 HAS NO ANSWERS
L16 STR



G1 Cb,Hy

Structure attributes must be viewed using STN Express query preparation.

```
=> s l16
SAMPLE SEARCH INITIATED 12:13:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       12 TO ITERATE

100.0% PROCESSED       12 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           33 TO      447
PROJECTED ANSWERS:               0 TO        0

L17            0 SEA SSS SAM L16

=> s l16 sss full
FULL SEARCH INITIATED 12:13:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      160 TO ITERATE

100.0% PROCESSED      160 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

L18            1 SEA SSS FUL L16

=> d his

     (FILE 'HOME' ENTERED AT 11:58:23 ON 25 JUN 2006)

     FILE 'REGISTRY' ENTERED AT 11:58:36 ON 25 JUN 2006
L1               STRUCTURE UPLOADED
L2             1 S L1
L3             3 S L1 SSS FULL
L4               STRUCTURE UPLOADED
L5            11 S L4
L6           170 S L4 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 12:00:18 ON 25 JUN 2006
L7             2 S L3
L8            35 S L6
```

```
L9            28 S L8 AND PY<=2003
L10            0 S L9 AND P38 KINASE
L11            1 S L9 AND KINASE INHIBITORS
L12           11 S L9 AND US/PC

     FILE 'REGISTRY' ENTERED AT 12:10:53 ON 25 JUN 2006
L13              STRUCTURE UPLOADED
L14            1 S L13
L15            3 S L13 SSS FULL
L16              STRUCTURE UPLOADED
L17            0 S L16
L18            1 S L16 SSS FULL

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   335.20     786.81

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -10.50

FILE 'HCAPLUS' ENTERED AT 12:14:09 ON 25 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 Jun 2006  VOL 145 ISS 1
FILE LAST UPDATED: 23 Jun 2006  (20060623/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l15
L19            2 L15

=> s l18
L20            1 L18

=> d l19 ibib abs hitstr tot

L19  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:      2004:878161  HCAPLUS
DOCUMENT NUMBER:       141:366245
TITLE:                 Preparation of substituted quinazolines as p38 kinase
                       inhibitors
```

INVENTOR(S): Dunn, James Patrick; Goldstein, David Michael; Stahl, Christoph Martin; Trejo-Martin, Teresa Alejandra
PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004209904	A1	20041021	US 2004-824731	20040415
AU 2004230209	A1	20041028	AU 2004-230209	20040408
CA 2522522	AA	20041028	CA 2004-2522522	20040408
WO 2004092144	A2	20041028	WO 2004-EP3779	20040408
WO 2004092144	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1620408	A2	20060201	EP 2004-726448	20040408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009580	A	20060418	BR 2004-9580	20040408
CN 1774425	A	20060517	CN 2004-80010341	20040408

PRIORITY APPLN. INFO.: US 2003-463467P P 20030416
WO 2004-EP3779 W 20040408

OTHER SOURCE(S): MARPAT 141:366245
GI



I



II

AB The title compds. I [R4, R5 = H, halo, CN, haloalkyl, or haloalkoxy (but are not both hydrogen); R6, R7 = alkyl, halo, CN, etc.; Q = a non-aromatic moiety; m = 0-3; n = 0-2] which are useful as p38 kinase inhibitors, were prepared and formulated. E.g., a multi-step synthesis of II, starting from Me 5-chloro-2-nitrobenzoate and 2,4-difluorophenol, which showed IC50 of <0.10 μM against p38 MAP kinase, was given.

IT **778639-20-6P 778639-21-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted quinazolines as p38 kinase inhibitors)

RN 778639-20-6 HCAPLUS
CN 1,2-Propanediol, 3-[[6-(2,4-difluorophenoxy)-2-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 778639-21-7 HCAPLUS
CN 2-Quinazolinamine, 6-(2,4-difluorophenoxy)-N-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)



L19 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:582372 HCAPLUS
DOCUMENT NUMBER: 142:155900
TITLE: Synthesis and phenotypic screening of a guanine-mimetic library
AUTHOR(S): Miller, Stephen C.; Mitchison, Timothy J.
CORPORATE SOURCE: Department of Cell Biology and Institute of Chemistry and Cell Biology, Harvard Medical School, Boston, MA, 02115, USA
SOURCE: ChemBioChem (2004), 5(7), 1010-1012
CODEN: CBCHFX; ISSN: 1439-4227
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:155900
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Guanine-derived small mols. play important roles in many aspects of cellular function. Proteins that bind guanine and its derivs. control a wide variety of cellular processes, and compds. that disrupt this binding would be valuable research tools as well as potential pharmaceuticals. A split-pool library of 270 6-substituted-2-amino-4(3H)-quinazolinones (I) (R1 = residue of thiol, phenol, or primary alcs.; R2 = aryl or alkyl; e.g. R1 = 3,4-dimethylphenyl, R2 = 3,4,5-trimethoxyphenyl, benzyl; R1 = isobutylthio, R2 = 3-acetylphenyl; R1 = cyclohexylthio, R2 = 4-chlorophenyl) was prepared by aza-Wittig-mediated solid-phase synthesis which involves (1) nucleophilic aromatic substitution of a resin-bound 5-fluoro-2-nitrobenzamide with a variety of thiols, phenols, and primary alcs., (2) generation of a resin-bound iminophosphorane (II) (P = resin) by treatment with Ph3P/Cl3CCCl3/imidazole (3 h, 4°), (3) aza-Wittig reaction of the iminophosphoranes with one of 15 isocyanates (R2-NCO) to yield a carbodiimide (III) (P = resin) followed by intermol. O-attack instead of the desired N attack to the carbodiimide to yield an 4-imino-4H-3,1-benzoxazine (IV), and (4) DBU-mediated isomerization to the desired 2-amino-4(3H)-quinazolinone (V) (P = resin) followed by resin cleavage. The compds. I were cell-permeable guanine-mimetics and screened for (a) the effect on the cytoskeleton and cell cycle progression by incubating the compds. with BS-C-1-(monkey) cells for 6 h, followed by fixing and staining for actin, DNA, and microtubules and (b) disruption of cellular trafficking. For example, I (R1 = isobutylthio, R2 = 3-acetylphenyl) disrupted both the actin and microtubule cytoskeleton, but did not arrest cells in mitosis.

IT **828261-87-6P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(solid-phase synthesis and phenotypic screening of guanine-mimetic library via aza-Wittig reaction of iminophosphoranes with isocyanates and DBU-mediated isomerization iminobenzoxazines)

RN 828261-87-6 HCAPLUS

CN 4(1H)-Quinazolinone, 6-(3,4-dimethylphenoxy)-2-[(phenylmethyl)amino]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l20 ibib abs hitstr tot

L20 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:582372 HCAPLUS
DOCUMENT NUMBER: 142:155900
TITLE: Synthesis and phenotypic screening of a guanine-mimetic library
AUTHOR(S): Miller, Stephen C.; Mitchison, Timothy J.
CORPORATE SOURCE: Department of Cell Biology and Institute of Chemistry and Cell Biology, Harvard Medical School, Boston, MA, 02115, USA
SOURCE: ChemBioChem (2004), 5(7), 1010-1012
CODEN: CBCHFX; ISSN: 1439-4227
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:155900
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Guanine-derived small mols. play important roles in many aspects of cellular function. Proteins that bind guanine and its derivs. control a wide variety of cellular processes, and compds. that disrupt this binding would be valuable research tools as well as potential pharmaceuticals. A split-pool library of 270 6-substituted-2-amino-4(3H)-quinazolinones (I) (R1 = residue of thiol, phenol, or primary alcs.; R2 = aryl or alkyl; e.g. R1 = 3,4-dimethylphenyl, R2 = 3,4,5-trimethoxyphenyl, benzyl; R1 = isobutylthio, R2 = 3-acetylphenyl; R1 = cyclohexylthio, R2 = 4-chlorophenyl) was prepared by aza-Wittig-mediated solid-phase synthesis which involves (1) nucleophilic aromatic substitution of a resin-bound 5-fluoro-2-nitrobenzamide with a variety of thiols, phenols, and primary alcs., (2) generation of a resin-bound iminophosphorane (II) (P = resin) by treatment with Ph3P/Cl3CCCl3/imidazole (3 h, 4°), (3) aza-Wittig reaction of the iminophosphoranes with one of 15 isocyanates (R2-NCO) to yield a carbodiimide (III) (P = resin) followed by intermol. O-attack instead of the desired N attack to the carbodiimide to yield an 4-imino-4H-3,1-benzoxazine (IV), and (4) DBU-mediated isomerization to the desired 2-amino-4(3H)-quinazolinone (V) (P = resin) followed by resin cleavage. The compds. I were cell-permeable guanine-mimetics and screened for (a) the effect on the cytoskeleton and cell cycle progression by incubating the compds. with BS-C-1-(monkey) cells for 6 h, followed by fixing and staining for actin, DNA, and microtubules and (b) disruption of cellular trafficking. For example, I (R1 = isobutylthio, R2 = 3-acetylphenyl) disrupted both the actin and microtubule cytoskeleton, but did not arrest cells in mitosis.

IT **828261-87-6P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(solid-phase synthesis and phenotypic screening of guanine-mimetic library via aza-Wittig reaction of iminophosphoranes with isocyanates and DBU-mediated isomerization iminobenzoxazines)

RN 828261-87-6 HCAPLUS
CN 4(1H)-Quinazolinone, 6-(3,4-dimethylphenoxy)-2-[(phenylmethyl)amino]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.39	807.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.25	-12.75

STN INTERNATIONAL LOGOFF AT 12:15:27 ON 25 JUN 2006